

National Institutes of Health National Cancer Institute Bethesda, Maryland 20892 Building 31 Room 11A48 August 27, 1990

Mrs. Albert Lasker The Albert and Mary Lasker Foundation 866 United Nations Plaza New York, NY 10017

Dear Mrs. Lasker:

This letter is to invite you to attend and participate in a workshop on cancer vaccines being sponsored by the National Cancer Institute, to be held October 29-30, 1990 at the Hyatt Regency Hotel in Bethesda, Maryland.

Vaccination is a classical technique to prevent infectious disease. It has been used successfully against a variety of bacterial and viral diseases. It is important that we now give serious consideration to the utilization of a vaccine approach for cancer prevention and control.

Recent advances in molecular biology and immunology, as well as recent results with tumor vaccines in some clinical trials and in preclinical animal tumor models, provide a strong impetus for focusing efforts and resources on vaccines as an important new approach to the prevention and treatment of cancer. Such cancer vaccines would be aimed at preventing the recurrence and metastatic spread of cancer in patients diagnosed with a primary tumor, and at preventing the development of cancer in individuals at high risk for malignant disease. At this meeting, a number of scientific experts will provide the most up-to-date information on topics such as viral vaccines, tumor antigens as vaccine targets, stimulation of activated cells, and prospects for cancer vaccine development. In addition, participants will be encouraged to suggest fruitful areas for future investigation, as well as necessary resources to support these investigations.

Because of your interest in and support for cancer research, I wanted to bring this important meeting to your attention, and to invite you to attend and participate. You will receive an accompanying letter from Dr. Jack Gruber, Chief of NCI's Biological Carcinogenesis Branch, which will provide details of the meeting arrangements. I hope you can reserve October 29 and 30 for this purpose, and I look forward to seeing you there.

Sincerely yours,

Samuel Broder, M.D.

Director

National Cancer Institute